Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone
Autore:
Waeber, B; Aschwanden, R; Sadecky, L; Ferber, P;
Indirizzi:
Univ Lausanne Hosp, Div Clin Pathophysiol & Med Teaching, CH-1011 Lausanne, Switzerland Univ Lausanne Hosp Lausanne Switzerland CH-1011 11 Lausanne, Switzerland Univ Hosp Oberbipp, Oberbipp, Switzerland Univ Hosp Oberbipp Oberbipp Switzerland Oberbipp, Oberbipp, Switzerland Univ Hosp Monthey, Monthey, Switzerland Univ Hosp Monthey Monthey Switzerland osp Monthey, Monthey, Switzerland Novartis Pharma Schweiz AG, Dept Med, Bern, Switzerland Novartis Pharma Schweiz AG Bern Switzerland Dept Med, Bern, Switzerland
Titolo Testata:
JOURNAL OF HYPERTENSION
fascicolo: 11, volume: 19, anno: 2001,
pagine: 2097 - 2104
SICI:
0263-6352(200111)19:11<2097:COHOBW>2.0.ZU;2-T
Fonte:
ISI
Lingua:
ENG
Soggetto:
CONVERTING ENZYME-INHIBITION; BLOOD-PRESSURE; ANGIOTENSIN; RECEPTOR; RENIN; MONOTHERAPY; BLOCKADE;
Keywords:
hypertension; antihypertensive therapy; clinical trial; office blood pressure; home blood pressure; diuretic; angiotensin converting enzyme inhibitor; angiotensin II receptor antagonist; AT(1)-receptor;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Life Sciences
Citazioni:
25
Recensione:
Indirizzi per estratti:
Indirizzo: Waeber, B Univ Lausanne Hosp, Div Clin Pathophysiol, PPA BH-19, CH-1011 Lausanne, Switzerland Univ Lausanne Hosp PPA BH-19 Lausanne Switzerland CH-1011 rland
Citazione:
B. Waeber et al., "Combination of hydrochlorothiazide or benazepril with valsartan in hypertensive patients unresponsive to valsartan alone", J HYPERTENS, 19(11), 2001, pp. 2097-2104

Abstract

Objective The aim of this open multicentric study was to investigate the efficacy and safety of the addition of an angiotensin converting enzyme (ACE) inhibitor (benazepril, 10 mg/day) or a diuretic (hydrochlorothiazide, 12.5 mg/day) for 4 weeks in patients with mild to moderate essential hypertension having been treated for 4 weeks by an angiotensin II antagonist (valsartan, 80 mg/day) but still having a diastolic blood pressure (BP) > 90 mmHg on this medication given alone. Methods A total of 327 patients were included in the trial and 153 patients (46%) had their diastolic BP less than or equal to 90 mmHg after 4 weeks of valsartan monotherapy. These patients continued the same treatment regimen for the next 4 weeks, but no further blood pressure reduction was observed. The remaining patients were randomized to either the valsartan-hydrochlorothiazide or the valsartan-benazepril combination. Results The two combinations induced an additional significant BP reduction, which was of similar magnitude for diastolic BP (-4.5 during valsartan-hydrochlorothiazide treatment and -3.3 mmHg during valsartan-benazepril treatment), but of greater magnitude for systolic BP during valsartan-hydrochlorothiazide (-6.77 mmHg) than during valsartan-benazepril coadministration (-3.2 mmHg). At the end of the trial, the BP of the responders to the valsartan monotherapy was lower than that of patients having required a combination therapy. Valsartan given alone or in association with hydrochlorothiazide or benazepril was well tolerated. Conclusion These data therefore show that in patients not responding sufficiently to angiotensin II receptor blockade BP can be further and safely lowered by adding a small dose of a diuretic or an ACE inhibitor, with the diuretic-containing combination tending to being more effective in controlling systolic BID. (C) 2001 Lippincott Williams & Wilkins.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 15/07/20 alle ore 14:49:47